Compare ELMD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | GALT |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 297.0M |
| IPO Year | 2010 | 2008 |
| Metric | ELMD | GALT |
|---|---|---|
| Price | $27.57 | $4.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $36.00 | $8.50 |
| AVG Volume (30 Days) | 108.3K | ★ 298.4K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.94 | 36.84 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $20.77 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $23.01 | $2.03 |
| 52 Week High | $47.40 | $7.13 |
| Indicator | ELMD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 55.88 |
| Support Level | $27.14 | $2.74 |
| Resistance Level | $30.26 | $4.35 |
| Average True Range (ATR) | 0.99 | 0.26 |
| MACD | 0.39 | -0.02 |
| Stochastic Oscillator | 79.41 | 45.80 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.